Market Access Europe: It's Not Just About Price

Date: May 22, 2011
Pages: 71
Price:
US$ 795.00
License [?]:
Publisher: FirstWord
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M5BDAB8E56FEN
Leaflet:

Download PDF Leaflet

Market Access Europe: It's Not Just About Price
“May you live in interesting times.”

Considered a curse by some, the saying could also be a blessing—especially when it comes to the evolving world of market access in Europe.

Given its complex geo-political situation, position in the global economy and number of voices to be heard, market access in Europe is both an environment of great hurdles—and great potential. While price and cost containment are major factors tackled by administrations and the pharmaceutical industry alike, it is only part of the story.

The rest of the tale is as multi-faceted as the region itself. National reimbursement policies that vary widely from country to country, payer restrictions and health care legislation have created an environment that can no longer focus solely on price. The result is a growing awareness in the industry of the importance of developing strategies that prepare the market, ensure there are no hidden payer issues and which pre-empt stakeholder concerns.

In Market Access Europe: It’s Not Just About Price, FirstWord casts a critical eye on the rapidly changing European environment to consider the key drivers and barriers to market access. The wide-ranging report addresses all major areas of market access in Europe, from value demonstration and partnership to price reference issues, the importance of communicating value and pan-European versus local approaches. The study includes interviews and access to some of the most senior and well-respected industry figures from PharmaPrice International, Novartis, Janssen and Axon Communications, amongst others. Concisely written, the report offers the industry discussions of major trends, insight into the pros and cons of specific approaches and most importantly of all, a thorough overview of the current state of the environment.

Scope

The report includes:
  • A full report on every aspect of market access in Europe
  • Insight into the pros and cons of specific approaches
Key features:
  • Expert opinion on all major areas of concern in market access in Europe
  • Detailed discussion of price and cost containment issues with a focus on value demonstration and partnership
  • Case studies that highlight successful approaches
  • Overview diagrams and up-to-date statistics to illustrate the scope of changes to the market
  • Several key academic and industry references for further reading and detail

EXECUTIVE SUMMARY

THE EVOLUTION OF MARKET ACCESS

WHAT IS MARKET ACCESS?

PHARMACEUTICAL COMPANY ALIGNMENT TO THE EXTERNAL ENVIRONMENT

DEMONSTRATING AND COMMUNICATING VALUE

REGIONAL DIFFERENCES AND CHALLENGES


Expenditure on pharmaceuticals
Drug utilization
Approaches to price control
  Fixed pricing
  Cost effectiveness/cost benefit analysis/measurement
  Profit caps, rebates and reductions
  Reference pricing

MARKET ACCESS DYNAMICS

Patient- versus product-centric approaches to market access
  The industry view
  Patient and provider view
Pan-European vs. local approaches
  Healthcare systems view
  Pharmaceutical industry view

KEY MARKET ACCESS CHALLENGES AND OPPORTUNITIES

HTA: the challenges and the future
  Efforts to create a European approach to HTA
  Most believe that HTA should be driven by national needs
Pricing & reimbursement
Price controls
  International reference pricing
    Price interdependencies between countries
    Value Based Pricing: A new level of pricing sophistication
  Therapeutic/internal reference pricing and therapeutic substitution
  Parallel imports
  Risk share schemes
  Disease management
    Where can industry partner?
Value: Balancing the short term and the long term
  Generic substitution
    Generic-drug companies position in new drug development
    Time for a new partnership model?

CRITICAL CONSIDERATIONS FOR APPROACHES TO MARKET ACCESS

Societal expectations
Government policies
Patient engagement
Payer engagement
Prescriber engagement
Long term partnerships between healthcare providers and industry are the way forward

CHALLENGES FOR INDUSTRY AND GOVERNMENTS

Continued innovation
Generic erosion of brands, new generics biosimilars

THE NEED FOR AN HOLISTIC APPROACH BY THE PHARMACEUTICAL INDUSTRY

LOOKING AHEAD: LINKING PRICE AND VALUE THROUGH PARTNERSHIP AND OUTCOMES

Partnership
Value based pricing methodologies
Patient-reported outcomes?demonstrating value well beyond price
Skip to top


Ask Your Question

Market Access Europe: It's Not Just About Price
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: